Register to get unlimited access to all of Citywire’s fund manager database. Registration is free and only takes a minute.

Polar Capital Biotechnology R USD

Ranked 10 out of 39 in - Biotechnology over 12 months
All calculations are in USD unless stated

Managed by

David Pinniger

David Pinniger joined Polar Capital in 2013 and is manager of the Polar Capital Biotechnology Fund. Prior to joining Polar Capital, he worked at SV Life Sciences, Abingworth and Morgan Stanley. David holds a first class honours degree in Human Sciences from the University of Oxford and is a CFA charterholder.


The investment objective of the Fund is to preserve capital and achieve long term capital appreciation.The Fund will seek to achieve its investment objective by investing in a globally diversified portfolio of biotechnology, diagnostics and life sciences tools companies.

Showing fund performance globally. You can view performance in individual jurisdictions.


Biotechnology over : 31/03/2017 - 31/03/2018

Total Return

Quarterly Performance

to 31/03/2018 Annual Q1 Q2 Q3 Q4
2018 6.3%
2017 30.1% 14.6% 4.9% 8.9% -0.6%
2016 -7.9% -18.9% 2.7% 13.4% -2.5%
2015 12.4% 13.6% 7.7% -16.5% 9.9%
2014 47.5% 18.3% 4.7% 5.7% 12.6%

Month by Month Performance

Returns Vs Risk

Registered For Sale In

  1. Austria
  2. Belgium
  3. Denmark
  4. Finland
  5. France
  6. Germany
  7. Guernsey
  8. Ireland
  9. Italy
  10. Jersey
  11. Luxembourg
  12. Netherlands
  13. Norway
  14. Singapore
  15. Spain
  16. Sweden
  17. Switzerland
  18. United Kingdom

Fund Info

  • Launch date31/10/2013
  • Share Class size352Mn
  • Base currencyUSD

Purchase Info

  • Min. initial investment0
  • Min. regular additional investment0


  • Annual management1.50%
  • Initial investment5

Related News

Selector snapshot: fantastic boutiques and where to find them

The latest one-to-one delves into uncovering lesser-known firms from across Europe.

Performance is for the period shown (month end to month end, bid/bid, gross income reinvested, calculated in USD).